Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P03971: Variant p.Val477Ala

Muellerian-inhibiting factor
Gene: AMH
Feedback?
Variant information Variant position: help 477 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Valine (V) to Alanine (A) at position 477 (V477A, p.Val477Ala). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (V) to small size and hydrophobic (A) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In PMDS1. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 477 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 560 The length of the canonical sequence.
Location on the sequence: help AADGPCALRELSVDLRAERS V LIPETYQANNCQGVCGWPQS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         AADGPCALRELSVDLRAERSVLIPETYQANNCQGVCGWPQS

Mouse                         -TDGPCALRELSVDLRAERSVLIPETYQANNCQGACAWPQS

Rat                           -TDGLCALRELSVDLRAERSVLIPETYQANNCQGACAWPQS

Pig                           VSNGPCALRELSVDLRAERSVLIPETYQANNCQGTCGWPQS

Bovine                        AADGPCALRELSVDLRAERSVLIPETYQANNCQGACGWPQS
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 452 – 560 Muellerian-inhibiting factor
Disulfide bond 462 – 526
Mutagenesis 472 – 472 R -> D. Little effect on AMH signaling.
Mutagenesis 478 – 478 L -> A. Abolishes AMH signaling. Does not induce regression of the Muellerian duct.
Mutagenesis 481 – 481 E -> A. Shows a slight decrease in AMH signaling. Affects slightly Mullerian duct regression.
Mutagenesis 481 – 481 E -> RY. Decreases AMH signaling.
Mutagenesis 484 – 484 Q -> S. Little effect on AMH signaling.
Beta strand 472 – 479



Literature citations
Molecular genetics of the persistent Mullerian duct syndrome: a study of 19 families.
Imbeaud S.; Carre-Eusebe D.; Rey R.; Belville C.; Josso N.; Picard J.-Y.;
Hum. Mol. Genet. 3:125-131(1994)
Cited for: VARIANTS PMDS1 GLY-12; PRO-70; VAL-101; TRP-123; CYS-167; CYS-194 AND ALA-477;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.